Medicine and Dentistry
Positron Emission Tomography
100%
Positron Emission Tomography-Computed Tomography
83%
Neoplasm
71%
Polyethylene Terephthalate
68%
Fluorodeoxyglucose F 18
50%
Radiation Therapy
48%
Cervical Cancer
47%
Diseases
39%
Tumor
29%
Pelvis
28%
Fluorine-18
28%
Neuroendocrine Tumor
27%
Gallium 68
26%
Carcinoma
26%
Fluorodeoxyglucose
26%
Computer Assisted Tomography
23%
Recurrent Disease
22%
Prostate Cancer
21%
Scintigraphy
21%
Brachytherapy
20%
Metastatic Carcinoma
20%
Magnetic Resonance Imaging
20%
Cancer
19%
Malignant Neoplasm
18%
Overall Survival
17%
Heart Muscle Blood Flow
16%
Radioactive Tracer
16%
Oncology
15%
Nuclear Medicine
15%
Lymph Node
14%
Lutetium 177
13%
Prostate Specific Membrane Antigen
13%
Cervix
12%
Technetium-99
12%
Coronary Artery Disease
12%
Standardized Uptake Value
12%
Uterine Cervix
11%
Somatostatin Receptor
11%
Non Small Cell Lung Cancer
11%
Breast Cancer
11%
Molecular Imaging
11%
Treatment Planning
10%
Uterine Cervix Carcinoma
10%
Biological Marker
10%
Radionuclide Therapy
10%
Radioisotope
10%
Biopsy Technique
10%
Single-Photon Emission Computed Tomography
10%
Radiopharmaceutical
9%
Clinical Trial
9%
Chemoradiotherapy
9%
Peptide Receptor
9%
Distant Metastasis
9%
Lung
9%
Progression Free Survival
9%
Lymph Node Metastasis
9%
Primary Tumor
9%
Uterine Cancer
9%
Intensity Modulated Radiation Therapy
8%
Prognostic Factor
8%
Treatment Response
8%
Dosimetry
8%
Pediatrics
8%
Heart Muscle Perfusion
8%
CT
8%
Positron Emission Tomography - Magnetic Resonance Imaging
7%
Radiology
7%
Low Drug Dose
7%
Coronary Circulation
7%
Drug Megadose
6%
Tetraxetan
6%
Pulmonary Embolism
6%
Paraaortic Lymph Node
6%
Disease Free Survival
6%
Receptor
6%
Bladder
6%
Myocardial Perfusion Imaging
6%
Castration Resistant Prostate Cancer
6%
External Beam Radiotherapy
6%
Amyloid Protein
6%
Bone Metastasis
5%
Myocardium
5%
Cardiovascular System
5%
Radioligand
5%
Squamous Cell Carcinoma
5%
Bone Scintigraphy
5%
Indium 111
5%
Colorectal Carcinoma
5%
Solid Malignant Neoplasm
5%
Implant
5%
Health Care Cost
5%
Liver Metastasis
5%
Lung Cancer
5%
Platelet
5%
Keyphrases
Positron Emission Tomography
69%
Positron Emission Tomography-computed Tomography (PET-CT)
67%
Tumor
50%
Cervical Cancer
46%
Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)
30%
Cervical Carcinoma
28%
Irradiation
25%
Neuroendocrine Tumor
20%
Computed Tomography
19%
Radiation Therapy
19%
18F-FDG PET-CT
19%
18F-fluorodeoxyglucose Positron Emission Tomography (18F-FDG PET)
17%
Overall Survival
17%
Fluorodeoxyglucose
16%
Prostate-specific Antigen
16%
Myocardial Blood Flow
16%
Brachytherapy
15%
Radiotherapy
15%
SUVmax
15%
Lutetium-177 (177Lu)
14%
Standardized Uptake Value
13%
18F-fluorodeoxyglucose (18F-FDG)
13%
Single-photon Emission Computed Tomography (SPECT)
12%
Chemotherapy
12%
Nuclear Medicine
12%
Distant Metastasis
12%
Magnetic Resonance Imaging
11%
Peptide Receptor Radionuclide Therapy
11%
Radiopharmaceuticals
11%
PET Imaging
11%
PET-MRI
11%
Liver
10%
Technetium-99m
10%
Progression-free Survival
10%
Prostate Cancer
10%
Prognostic Factors
10%
Molecular Imaging
9%
Scintigraphy
9%
Radiation Dose
8%
Gallium-68
8%
Breast Cancer
8%
Non-small Cell Lung Cancer (NSCLC)
8%
Primary Tumor
8%
Coronary Artery Disease
8%
Pelvis
8%
Oncologic
7%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
7%
Dosimetry
7%
Theranostics
7%
Perfusion
7%
Disease-free Survival
7%
Radiation Therapy Oncology Group
7%
Intensity-modulated Radiation Therapy
7%
Positron Emission tomography-CT
7%
Confidence Interval
7%
Radiotracer
7%
Lung
7%
Intracavitary
6%
Somatostatin Receptor
6%
Radionuclides
6%
Clinical Outcomes
6%
Fluoro
6%
Metastatic Disease
6%
Tumor Response
6%
Myocardial Flow Reserve
6%
Stage IB
6%
Phase II Study
6%
Endometrial Cancer
6%
Whole-body
6%
Patient Management
6%
Metastasis
6%
Tumor Volume
6%
Lymph Node Metastasis
6%
High Dose
6%
PET Image
6%
Invasive Cervical Cancer
6%
Left Ventricular Function
6%
Clinical Application
6%
Clinical Trials
6%
Myocardial Perfusion
6%
Oncology
6%
Concurrent Chemotherapy
6%
Imaging Modalities
6%
Prostate Cancer Patients
6%
Imaging Studies
5%
Recurrent Disease
5%
FDG Uptake
5%
Metabolic Tumor Volume
5%
Malignancy
5%
Pelvic Lymph Nodes
5%
Pulmonary Embolism
5%
Radioligand Therapy
5%
FDG PET-CT
5%
Para-aortic Lymph Node
5%
Neuroendocrine Neoplasms
5%
Multivariate Analysis
5%
Locally Advanced Cervical Cancer
5%
National Oncologic PET Registry
5%
Cisplatin
5%
Cold Pressor
5%